Evidence map›Paper›PMID 41345806›Full record

ArticleNature cancer2025

Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy.

Federico Giovannoni, Craig A Strathdee, Camilo Faust Akl, Brian M Andersen, Zhaorong Li, Hong-Gyun Lee, María Florencia Torti, Joseph M Rone, Pere Duart-Abadia, Martina Molgora and 16 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. oHSV-1-modulated mVirology journal · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Federico Giovannoni *Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Craig A Strathdee *Oncorus, Inc., Andover, MA, USA.
Camilo Faust Akl *Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5883-4441
Brian M AndersenAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1162-9061
Zhaorong LiAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Hong-Gyun LeeAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
María Florencia TortiAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Joseph M RoneAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Pere Duart-AbadiaAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1033-121X
Martina MolgoraDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0003-1230-1313
Linxing KongOncorus, Inc., Andover, MA, USA.
Michael FloydOncorus, Inc., Andover, MA, USA.
Jian TengOncorus, Inc., Andover, MA, USA.
Yulia GyulakianOncorus, Inc., Andover, MA, USA.
Peter GrzesikOncorus, Inc., Andover, MA, USA.ORCID http://orcid.org/0000-0002-1337-8622
Terry FarkalyOncorus, Inc., Andover, MA, USA.
Agnieszka DenslowOncorus, Inc., Andover, MA, USA.
Sonia FeauOncorus, Inc., Andover, MA, USA.
Irene Rodriguez-SanchezOncorus, Inc., Andover, MA, USA.
Judith JacquesOncorus, Inc., Andover, MA, USA.
Marco ColonnaDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0001-5222-4987
Edward M KennedyOncorus, Inc., Andover, MA, USA.
Tooba CheemaOncorus, Inc., Andover, MA, USA.
Lorena LernerOncorus, Inc., Andover, MA, USA.ORCID http://orcid.org/0000-0002-9474-2018
Christophe QuévaOncorus, Inc., Andover, MA, USA. christophe@ovietx.com.ORCID http://orcid.org/0000-0002-3693-2972
Francisco J QuintanaAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. fquintana@rics.bwh.harvard.edu.ORCID http://orcid.org/0000-0001-8156-0736

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is an aggressive, immunotherapy-resistant brain tumor. Here, we engineered an oncolytic virus platform based on herpes simplex virus 1 for GBM viroimmunotherapy. We mutated the highly cytopathic MacIntyre strain to increase spread and oncolytic activity, limit genetic drift, prevent neuron infection and enable PET tracing. We incorporated microRNA target cassettes to attenuate replication in healthy brain cells. Moreover, we engineered the gD envelope protein to specifically target GBM using EGFR-specific or integrin-specific binders. Lastly, we incorporated five immunomodulators to remodel the tumor microenvironment (TME) by locally expressing IL-12, anti-PD1, a bispecific T cell engager, 15-hydroxyprostaglandin dehydrogenase and anti-TREM2 to target T cells and myeloid cells in the GBM TME. A single intratumoral injection increased survival in GBM preclinical models, while promoting tumor-specific T cell, natural killer cell and myeloid cell responses in the TME. In summary, we engineered a retargeted, safe and traceable oncolytic virus with strong cytotoxic and immunostimulatory activities for GBM immunotherapy.

Indexed as

Brain NeoplasmsGlioblastomaImmunotherapyOncolytic VirotherapyOncolytic VirusesTumor MicroenvironmentAnimalsCell Line, TumorHerpesvirus 1, HumanHumansMiceXenograft Model Antitumor Assays

Identifiers

PMID41345806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.